[Phase III trial of 99mTc-rhenium colloid for lymphoscintigraphy].
A multicenter study was carried out on 191 patients (196 examinations) with lymphatic system disorders to evaluate the efficacy and safety of 99mTc-rhenium Colloid, a tracer for lymphoscintigraphy (TCK-17). Local pain and swelling occurred at the site of injection in 79.6% and 5.1% of patients, respectively, and 2 patients experienced mild fever. The accuracy was calculated on the basis of the results obtained by other diagnostic methods. Lymphoscintigraphy using TCK-17 was sensitive diagnostic procedures, but low specificity. The efficacy was classified into five grades: "Excellent", "Good", "Moderate", "Equivocal", and "Poor". 67.3% of all examination were evaluated as "Excellent" or "Good". This study revealed TCK-17 was a useful radiopharmaceutical for lymphoscintigraphy because of its safety and effectiveness.
Watanabe
K
K
Department of Radiology, Miyazaki Medical College.
Noikura
T
T
Yamashita
S
S
Fukunaga
M
M
Orita
K
K
Nakano
S
S
Kawana
M
M
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D008198:Lymph Nodes / Q000000981:diagnostic imaging; D008206:Lymphatic Diseases / Q000000981:diagnostic imaging*; D008207:Lymphatic Metastasis; D008228:Lymphoma, Non-Hodgkin / Q000000981:diagnostic imaging / Q000473:pathology; D061305:Lymphoscintigraphy; D008297:Male; D008875:Middle Aged; D012211:Rhenium / Q000009:adverse effects; D012983:Soft Tissue Neoplasms / Q000000981:diagnostic imaging; D013274:Stomach Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology; D013667:Technetium / Q000009:adverse effects; D017556:Technetium Compounds
D017556:Technetium Compounds; C030576:technetium Tc 99m rhenium colloid; D012211:Rhenium; D013667:Technetium